GZR101 vs Insulin glargine (Toujeo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

GZR101

Developed by Gan & Lee Pharmaceuticals

Phase 2 in Type 2 Diabetespeptide
Partial signal

NCT06199505 · Phase 2 · completed

The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07387003 (registry estimate)

Reported efficacy

Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)

Result source: NCT06199505

Insulin glargine (Toujeo)

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT01499082 · Phase 3 · completed

The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.

Reported efficacy

Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)

Result source: NCT01499082

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGZR101Insulin glargine (Toujeo)
HbA1c, change-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
—Not reported
Body weight, change (kg)—Not reported—Not reported
HbA1c below 7%—Not reported—Not reported
Fasting plasma glucose, change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

GZR101
-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
Insulin glargine (Toujeo)
—Not reported

Body weight, change (kg)

GZR101
—Not reported
Insulin glargine (Toujeo)
—Not reported

HbA1c below 7%

GZR101
—Not reported
Insulin glargine (Toujeo)
—Not reported

Fasting plasma glucose, change

GZR101
—Not reported
Insulin glargine (Toujeo)
—Not reported

3-point MACE (% with event)

GZR101
—Not reported
Insulin glargine (Toujeo)
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. GZR101: 0 of 4 rows · Insulin glargine (Toujeo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGZR101Insulin glargine (Toujeo)
Dropout rate—
14.8%a
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
14.9%
NCT02451137 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs—
—a
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
2.6%
NCT02451137 · Phase 4 · registry result, not featured evidence
Serious AEs—
19.4%a
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
9.8%
NCT02451137 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs—
a
trauma 3.7%
cough 0.9%
gastroparesis 0.9%
NCT03013985 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

GZR101

HbA1c -1.56% vs -1.31% IDegAsp once-daily @ 16wk
absolute change · percentage points
NCT06199505 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-1.64% vs -1.59% IDegAsp twice-daily @ 16wk
NCT06199505 · Phase 2 · sponsor-reported, not registry data
-1.68% vs -1.59% IDegAsp twice-daily @ 16wk
NCT06199505 · Phase 2 · sponsor-reported, not registry data

Insulin glargine (Toujeo)

Daily Glucose mg/dL 10.32 vs 10.21 Glargine U100 mmol/L
absolute value · mmol/L
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 186 mg/dL as posted
show 6 more results
9.52 vs 9.13 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 171.6 mg/dL as posted
8.33 vs 7.46 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted
8.45 vs 8.64 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 152.3 mg/dL as posted
9.42 vs 10.92 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 169.71 mg/dL as posted
10.74 vs 10.75 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 193.53 mg/dL as posted
10.46 vs 9.69 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 188.46 mg/dL as posted
Time in Range 50.3% (n=92) vs 54.9% (n=84) Glargine U100 @ 12wk
absolute value · percentage points
NCT03013985 · Phase 4 · registry result, not featured evidence
Hypoglycemia Event Incidence 8.7% (n=92) vs 9.5% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
Severe Hypoglycemia Event Incidence 0% (n=92) vs 6% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
HbA1c Target Attainment Without Hypoglycemia 31.3% (n=1651) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
37.3% (n=1651) @ 26wk
NCT02451137 · Phase 4 · registry result, not featured evidence
HbA1c -1.4% (n=1651) @ 26wk
absolute change · percentage points
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
-1.29% (n=1651) @ 52wk
NCT02451137 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -2.71 mmol/L @ 26wk
absolute change · mmol/L
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48.9 mg/dL as posted
show 1 more result
-2.66 mmol/L @ 52wk*
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted
Weight 1.02 kg @ 26wk
absolute change · kg
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
1.51 kg @ 52wk
NCT02451137 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · Insulin glargine (Toujeo)'s landscape